Sharjah Breaks Global Record in Nutrition Quality Thanks to Innovative Food Techniques
10.4.2025 09:00:00 CEST | Business Wire | Press Release
Sharjah, a leading hub for innovation and excellence in the United Arab Emirates, is making a significant contribution to global food security and sustainability by producing an innovative wheat variety with an unprecedented protein content of 19.3%—the highest recorded worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250404373415/en/
Mleiha Wheat Farm in Sharjah
With growing interest from global food companies, Sharjah is looking into exporting its high-protein wheat to position itself as a key contributor in the international market. Several international certifications, including the HSP food quality certificate and the “Made in Emirates” label have recognized the emirate’s high food standards. The project also won the Best Innovation Award for Sustainability in the UAE, highlighting its impact on environmental protection and agricultural advancement.
Her Excellency Dr. Amna Al Dahak, UAE Minister of Climate Change and Environment, emphasized the project’s role in advancing climate-smart agriculture. She noted that the use of modern technologies, including AI-driven irrigation systems, has been instrumental in the project’s success, reducing water consumption by 30%.
Developed under the directive of His Highness Sheikh Dr. Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the project cultivated high-protein wheat on 1,428 hectares of desert land using advanced agricultural technologies. This season’s organic wheat harvest is expected to yield around 6,000 tonnes.
The new wheat variety, developed at the Mleiha Wheat Farm, is already being used in local products such as bread, pasta, and cereals, which have attracted both local and international manufacturers.
“Through this project, Sharjah has shown that innovation could overcome even the toughest farming challenges,” Al Dahak added. With an annual output of 15,200 tonnes, the farm now meets Sharjah’s entire wheat demand, significantly reducing reliance on imports.
The farm's success stems from the development of a unique wheat strain, ‘Sharjah 1,’ which is designed to withstand high salinity and drought conditions. A dedicated biotechnology lab has accelerated the genetic improvement process, evaluating over 1,450 wheat strains to select the best-performing varieties.
“Sharjah’s wheat has exceeded global standards, making it one of the most nutritionally valuable wheat varieties worldwide,” said Dr. Osama Hussein Qambar, an agricultural expert at the Sharjah Department of Agriculture and Livestock.
The farm also integrates other state-of-the art technologies, such as satellite thermal imaging, to optimise yield and quality. A weather monitoring system provides live forecasts, helping to protect crops from environmental fluctuations.
Further pictures can be found here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250404373415/en/
Contacts
Sabina Nallim
Media Relations Manager
Tel.: +49 30 65000434
s.nallim@mcgroup.com
http://www.mcgroup.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.mcgroup.com
&esheet=54233450&newsitemid=20250404373415&lan=en-US&anchor=http%3A%2F%2Fwww.mcg
roup.com&index=2&md5=31c3db6e48576175a9a17abb53478b3d
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom